JPWO2022136209A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022136209A5 JPWO2022136209A5 JP2023538150A JP2023538150A JPWO2022136209A5 JP WO2022136209 A5 JPWO2022136209 A5 JP WO2022136209A5 JP 2023538150 A JP2023538150 A JP 2023538150A JP 2023538150 A JP2023538150 A JP 2023538150A JP WO2022136209 A5 JPWO2022136209 A5 JP WO2022136209A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- asthma
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000006673 asthma Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 210000003979 eosinophil Anatomy 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000000743 Interleukin-5 Human genes 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128922P | 2020-12-22 | 2020-12-22 | |
| US63/128,922 | 2020-12-22 | ||
| US202163192854P | 2021-05-25 | 2021-05-25 | |
| US63/192,854 | 2021-05-25 | ||
| US202163220182P | 2021-07-09 | 2021-07-09 | |
| US63/220,182 | 2021-07-09 | ||
| US202163285513P | 2021-12-03 | 2021-12-03 | |
| US63/285,513 | 2021-12-03 | ||
| PCT/EP2021/086689 WO2022136209A1 (en) | 2020-12-22 | 2021-12-20 | Interleukin 5 binding protein dosage regimen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500912A JP2024500912A (ja) | 2024-01-10 |
| JPWO2022136209A5 true JPWO2022136209A5 (enrdf_load_stackoverflow) | 2024-12-18 |
Family
ID=86732980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538150A Pending JP2024500912A (ja) | 2020-12-22 | 2021-12-20 | インターロイキン５結合タンパク質の投与レジメン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240043524A1 (enrdf_load_stackoverflow) |
| EP (1) | EP4267184A1 (enrdf_load_stackoverflow) |
| JP (1) | JP2024500912A (enrdf_load_stackoverflow) |
| CA (1) | CA3199805A1 (enrdf_load_stackoverflow) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI799417B (zh) * | 2017-05-26 | 2023-04-21 | 英商葛蘭素史克智慧財產發展有限公司 | 生物製藥組成物及相關方法 |
| WO2019224724A1 (en) * | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions comprising antibody variants |
-
2021
- 2021-12-20 CA CA3199805A patent/CA3199805A1/en active Pending
- 2021-12-20 US US18/258,588 patent/US20240043524A1/en active Pending
- 2021-12-20 EP EP21844228.3A patent/EP4267184A1/en active Pending
- 2021-12-20 JP JP2023538150A patent/JP2024500912A/ja active Pending